Matches in SemOpenAlex for { <https://semopenalex.org/work/W2063887207> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W2063887207 endingPage "AB185" @default.
- W2063887207 startingPage "AB185" @default.
- W2063887207 abstract "The aim of this study was to investigate the immunogenicity and the drug-level of two anti-TNF therapies (Infliximab-IFX vs Etanercept-ETN) in the serum of patients attending the Rheumatology Area and included in this treatment option. Serum from 15 ETN and 13 IFX-treated patients were sent to the Immunology Laboratory. The IFX and ETN serum level and anti-IFX and anti-ETN antibodies were measured in all samples at the same time using PROMONITOR® IFX and ETN following manufacturer’s instructions. Samples were collected the day before next dose of drug was infused and remained frozen until analysis. 7/15 (46%) ETN-treated patients and 5/13 (38%) IFX-treated patients have level of ETN/IFX >=1.5 ugr/mL (therapeutic level for AR). 5/15 (33%) ETN and 5/13 (38%) IFX have levels between 0.1 and 1.5 (sub-therapeutic level). 3/15 ETN-treated (20%) and 3/13 (23%) IFX-treated patients were below the level of detection of the method. All patients below the level of detection in the IFX-group (3/13) have high level of Anti-IFX antibodies whereaspatients in the ETN group (3/15) were negative for Anti-ETN antibodies. Anti-TNF therapies are widely used for the treatment of patients with several rheumatologic conditions. Nowadays, these biological treatments represent a high proportion of the budget of the health care system. The possibility of a routine monitorization of levels of each drug and also the immunological response of patients against the different lines of treatment should be mandatory in order to choose the best cost-effectiveness strategy and to benefit the patients from a tailored therapy." @default.
- W2063887207 created "2016-06-24" @default.
- W2063887207 creator A5018408523 @default.
- W2063887207 creator A5057118725 @default.
- W2063887207 creator A5079268052 @default.
- W2063887207 creator A5087703458 @default.
- W2063887207 creator A5088725427 @default.
- W2063887207 date "2014-02-01" @default.
- W2063887207 modified "2023-09-26" @default.
- W2063887207 title "Immunogenicity Analysis Of Two Anti-TNF (Infliximab vs Etanercept) Therapies In Rheumatologic Patients" @default.
- W2063887207 doi "https://doi.org/10.1016/j.jaci.2013.12.663" @default.
- W2063887207 hasPublicationYear "2014" @default.
- W2063887207 type Work @default.
- W2063887207 sameAs 2063887207 @default.
- W2063887207 citedByCount "0" @default.
- W2063887207 crossrefType "journal-article" @default.
- W2063887207 hasAuthorship W2063887207A5018408523 @default.
- W2063887207 hasAuthorship W2063887207A5057118725 @default.
- W2063887207 hasAuthorship W2063887207A5079268052 @default.
- W2063887207 hasAuthorship W2063887207A5087703458 @default.
- W2063887207 hasAuthorship W2063887207A5088725427 @default.
- W2063887207 hasBestOaLocation W20638872071 @default.
- W2063887207 hasConcept C126322002 @default.
- W2063887207 hasConcept C159654299 @default.
- W2063887207 hasConcept C17991360 @default.
- W2063887207 hasConcept C198451711 @default.
- W2063887207 hasConcept C203014093 @default.
- W2063887207 hasConcept C2777138892 @default.
- W2063887207 hasConcept C2777226972 @default.
- W2063887207 hasConcept C2777575956 @default.
- W2063887207 hasConcept C2780035454 @default.
- W2063887207 hasConcept C2780132546 @default.
- W2063887207 hasConcept C2780868878 @default.
- W2063887207 hasConcept C71924100 @default.
- W2063887207 hasConcept C90924648 @default.
- W2063887207 hasConcept C98274493 @default.
- W2063887207 hasConceptScore W2063887207C126322002 @default.
- W2063887207 hasConceptScore W2063887207C159654299 @default.
- W2063887207 hasConceptScore W2063887207C17991360 @default.
- W2063887207 hasConceptScore W2063887207C198451711 @default.
- W2063887207 hasConceptScore W2063887207C203014093 @default.
- W2063887207 hasConceptScore W2063887207C2777138892 @default.
- W2063887207 hasConceptScore W2063887207C2777226972 @default.
- W2063887207 hasConceptScore W2063887207C2777575956 @default.
- W2063887207 hasConceptScore W2063887207C2780035454 @default.
- W2063887207 hasConceptScore W2063887207C2780132546 @default.
- W2063887207 hasConceptScore W2063887207C2780868878 @default.
- W2063887207 hasConceptScore W2063887207C71924100 @default.
- W2063887207 hasConceptScore W2063887207C90924648 @default.
- W2063887207 hasConceptScore W2063887207C98274493 @default.
- W2063887207 hasIssue "2" @default.
- W2063887207 hasLocation W20638872071 @default.
- W2063887207 hasOpenAccess W2063887207 @default.
- W2063887207 hasPrimaryLocation W20638872071 @default.
- W2063887207 hasRelatedWork W1973470095 @default.
- W2063887207 hasRelatedWork W1997375495 @default.
- W2063887207 hasRelatedWork W2015993259 @default.
- W2063887207 hasRelatedWork W2018600081 @default.
- W2063887207 hasRelatedWork W2039662997 @default.
- W2063887207 hasRelatedWork W2041941266 @default.
- W2063887207 hasRelatedWork W2095450130 @default.
- W2063887207 hasRelatedWork W2141436693 @default.
- W2063887207 hasRelatedWork W230393467 @default.
- W2063887207 hasRelatedWork W2341567294 @default.
- W2063887207 hasVolume "133" @default.
- W2063887207 isParatext "false" @default.
- W2063887207 isRetracted "false" @default.
- W2063887207 magId "2063887207" @default.
- W2063887207 workType "article" @default.